Deck
Wolters Kluwer sells subscriptions to the tax rules, clinical evidence, legal precedent and compliance data that regulated professionals depend on, delivered mostly as workflow software — 83% of revenue recurring and renewing above 90%.
At ten times earnings, the price implies a decline the cash-flow record never showed
A Gordon-growth solve on the ~$14.8bn market capitalisation and $1,584m of adjusted free cash flow implies perpetual FCF growth of roughly minus one to minus two percent at an 8.5–9% cost of equity, against a free-cash-flow record that compounded at 7.6% a year from 2016 to 2025. The same buyback engine that produced the record has drained total equity to $938m and lifted net debt to $4,728m — 2.0x EBITDA, the top of policy — so a growth disappointment now lands on a thinner cushion. Most of the potential return rides on that implied decline being wrong.
The re-rating turns on whether generative AI erodes proprietary expert content — or extends it
- The fear priced in: the discount reflects concern that generative AI commoditises proprietary reference content. About 41% of WKL revenue is human-facing digital content, and it discloses no machine-to-machine data layer of the kind that makes RELX's ~90% Risk division hard to disrupt.
- The company's answer: "Expert AI" — generative models grounded in WKL's own content with an expert in the loop. 70% of digital revenue is already AI-powered, and adoption is measurable: about 80 enterprises signed for UpToDate Expert AI, including 30 of the top 100 hospitals.
- Adoption is not yet monetisation: the sign-ups so far defend renewal above 90% more than they add new revenue; consumption pricing remains in test, so any growth lift is not yet in the numbers.
The discount maps to a real growth gap, not fear alone
On moat economics WKL sits inside its cohort — a 27.5% adjusted margin, free-cash conversion above 100%, renewal above 90%. Where it trails is growth: 6% organic in 2025 against RELX's 7% and Thomson Reuters' 7% (9% in its Big Three professional segments), and 5% in Legal against RELX's 9%. The roughly 40–55% multiple discount is the price of being a durable follower rather than a differentiated leader, while RELX, Thomson Reuters and Verisk re-rated back to 16x, 19x and 24x.
The 2026 plan halves the buyback that drove a third of last year's EPS growth
Five years of repurchases — about $4.9bn, 39m shares at an average $126 — compounded EPS but drained equity to $938m and lifted net debt to $4,728m. For 2026 management halved the buyback to $572m and raised product-development spend to 12–13% of revenue, guiding high-single-digit EPS growth rather than the double-digit the decade delivered. It frames this as reinvestment to defend the moat, not a retreat; the adjusted margin is still guided up toward 28%.
The first CEO change in 22 years, and a pay plan set to a lower EPS bar
- Orderly handover: Nancy McKinstry, CEO since September 2003, hands to insider Stacey Caywood — the former Health-division head who built UpToDate's Expert AI — while CFO Kevin Entricken, in place since 2013, stays for continuity on capital allocation.
- Pay encodes the slowdown: the 2026–2028 incentive plan targets a 9.1% adjusted-EPS CAGR, below the 10.5% just delivered over 2023–2025 — management's own scorecard now pays for high-single-digit growth.
- Alignment tested: the 2023–2025 long-term plan paid zero on total shareholder return — WKL ranked 15th of 16 peers — even as its EPS and ROIC targets were largely met.
A two-sided position that resolves on scheduled dates
- Both sides share the facts: a record operating year — 6% organic growth, a 27.5% margin, $6.22 adjusted EPS — repriced to about 10x while recovering peers sit at 16–24x. They part on what the growth gap means.
- The bull read: a partial re-rating toward peers on unchanged earnings is most of the return to the ~$115 consensus target; no earnings inflection is required.
- The bear read: the discount is earned — the cohort's slowest growth, an EPS algorithm re-weighted away from buybacks, and AI substitution that renewal above 90% may be masking.
The bulls' reply, in the same breath: Re-rating to a still-discounted 16x on unchanged adjusted EPS of $6.22 lifts the shares ~47% toward the ~$115 consensus with no earnings growth required, and WKL still matches the cohort on moat economics — 27.5% adjusted margin, >100% FCF conversion, >90% renewal.
Watchlist to re-rate: Half-year 2026 results on 5 August 2026 (group organic growth vs the 5% Q1 run-rate, and margin heading toward ~28%); Health and Legal & Regulatory renewal / net retention; and whether Legal and Tax organic converge toward the cohort's ~9% as Expert AI monetisation scales.